<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925583</url>
  </required_header>
  <id_info>
    <org_study_id>RADONK-Magellan_2020</org_study_id>
    <nct_id>NCT04925583</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location</brief_title>
  <acronym>MAGELLAN</acronym>
  <official_title>Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MAGELLAN is a phase-I dose escalation trial that aims to identify the maximum tolerated dose&#xD;
      (MTD) of MR-guided SBRT of ultracentral lung Tumors (primary objective). Thus, a maximum of&#xD;
      38 patients with ultracentral lung tumors (overlap of the planning target volume with the&#xD;
      proximal bronchial tree and/or esophagus) will receive MR-guided SBRT including gated dose&#xD;
      delivery and daily plan adaptation on a 0.35 MR-linac System. Dose levels are as follows:&#xD;
&#xD;
        -  0 (de-escalation): 10 x 5.0Gy&#xD;
&#xD;
        -  1 (start): 10 x 5.5Gy&#xD;
&#xD;
        -  2: 10 x 6.0Gy&#xD;
&#xD;
        -  3: 10 x 6.5Gy&#xD;
&#xD;
      Dose escalation is performed according to a time-to-event continual reassessment method&#xD;
      (TITE-CRM) with backup element. Patients are observed individually for 12 months to detect&#xD;
      potential dose limiting toxicity (DLT = primary endpoint) and for a total of 24 months to&#xD;
      detect potential tumor relapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stereotactic body radiotherapy (SBRT) is a well-established local treatment method for&#xD;
      early-stage NSCLC or lung metastases. However, clinicians are restricted in the utilization&#xD;
      of sufficiently high radiation doses when the lung tumor is in ultracentral location next to&#xD;
      radiosensitive organs-at-risk (OAR, e.g. the central airways or the esophagus). MR-guided&#xD;
      SBRT can minimize the dose to these OAR by advanced techniques to correct for interfractional&#xD;
      (daily plan adaptation) and intrafractional motion (respiratory gating, i.e. synchronization&#xD;
      of beam delivery to the patient's breathing). Consequently, the MAGELLAN trial uses MR-guided&#xD;
      SBRT to enable safe dose escalation to ultracentral lung tumors. The primary objective of&#xD;
      this phase I dose escalation trial is to detect the maximum tolerated dose of MR-guided SBRT&#xD;
      to ultracentral lung tumors with a dose limiting toxicity (DLT) rate = 35%. This dose should&#xD;
      yield the optimum balance between acceptable treatment toxicity and good tumor control. The&#xD;
      corresponding primary endpoint is the observation of the binary outcome dose-limiting&#xD;
      toxicity (DLT) within 12 months from start of radiation. Secondary objectives include&#xD;
      description of tumor control, patient survival and patient-reported outcomes, assessment of&#xD;
      longitudinal cardiopulmonary function and dosimetry evaluations. Exploratory objectives&#xD;
      include detection of early biomarkers of pulmonary toxicity and tumor response from&#xD;
      multiparamtetric thoracic MRI examinations as well as peripheral blood samples before and&#xD;
      early after treatment. A maximum of 38 adult patients may be accrued. Inclusion criteria&#xD;
      encompass indication for pulmonary SBRT, ultracentral lung tumor location defined as overlap&#xD;
      of the planning target volume (PTV) with the proximal bronchial tree or esophagus and a&#xD;
      maximum tumor diameter â‰¤ 5cm. MR-guided SBRT is delivered on a 0.35T MR-Linac (6MV linear&#xD;
      accelerator) with daily plan adaptation and gated dose delivery. Four dose levels may be&#xD;
      employed:&#xD;
&#xD;
        -  0 (de-escalation): 10 x 5.0Gy&#xD;
&#xD;
        -  1 (start): 10 x 5.5Gy&#xD;
&#xD;
        -  2: 10 x 6.0Gy&#xD;
&#xD;
        -  3: 10 x 6.5Gy&#xD;
&#xD;
      Dose level 0 represents a de-escalation step which is deemed safe by retrospective clinical&#xD;
      data. Dose level 3 confidently reaches a BED10 &gt; 100 Gy necessary for adequate local tumor&#xD;
      control in the lung according to hitherto data. Individual observation time for DLTs is 12&#xD;
      months. Dose escalation is performed in dose escalation cohorts consisting of three patients&#xD;
      (N = 3) and the first cohort starts at dose level 1 (10 x 5.5 Gy). A time-to-event continual&#xD;
      reassessment method (TITE-CRM) is used to recommend the dose level for the next cohort after&#xD;
      a cumulative observation time of 18 months. TITE-CRM accounts for all available data at any&#xD;
      given time to estimate DLT rates for each dose level and will recommend the dose level&#xD;
      closest to the MTD. Admissible patients who present during the cumulative observation time&#xD;
      are included as backup patients and treated on the dose level below the current&#xD;
      recommendation. An escalation with overdose control (EWOC) approach is applied to prevent&#xD;
      treatment with too toxic doses. According to the stopping criteria, patient accrual will be&#xD;
      stopped after including 36 patients or 40 months after the first subject in date (recruitment&#xD;
      of current dose escalation cohort may be completed), in case that estimation of the MTD is&#xD;
      sufficiently certain or if all dose levels appear too toxic. After patient accrual has been&#xD;
      stopped and all patients have completed their individual observation time, a final dose&#xD;
      recommendaton will be performed which represents the MTD estimate. During follow-up, patients&#xD;
      receive clinical assessments (3 monthly), thoracic CT- (3-monthly) and MR-imaging (after 3&#xD;
      months), one cardiology assessment (after 12 months), pulmonary function testing (12-monthly)&#xD;
      and peripheral blood samples (last treatment day, after 3 months) for a total of 2 years&#xD;
      after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation, Arm 1: Level 0, 5.0 Gy, 10 fractions Arm 2: Level 1, 5.5 Gy, 10 fractions Arm 3: Level 2, 6.0 Gy, 10 fractions Arm 4: Level 3, 6.5 Gy, 10 fractoins</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>For 12 months from the beginning of SBRT.</time_frame>
    <description>Observation of the binary outcome dose-limiting toxicity (DLT). DLTs are defined in a catalogue of mainly pulmonary, esophageal and cardiac toxicity based on the CTCAE in Version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local tumor control</measure>
    <time_frame>For 24 months upon enrollment</time_frame>
    <description>Total number of treated ultracentral tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional tumor control</measure>
    <time_frame>For 24 months upon enrollment</time_frame>
    <description>Number of tumor leasions in Lungs and Mediastinum excluding the treated ultracentral tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant tumor Control</measure>
    <time_frame>For 24 months upon enrollment</time_frame>
    <description>Number of Tumor leasions Outside lungs and mediastinum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>For 24 months upon enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>For 24 months upon enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ C-30</measure>
    <time_frame>For 24 months upon enrollment</time_frame>
    <description>Changes in quality of life following MR-guided ultracentral lung SBRT, according to EORTC QLQ C-30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-LC13</measure>
    <time_frame>For 24 months upon enrollment</time_frame>
    <description>Changes in quality of life following MR-guided ultracentral lung SBRT, according to EORTC QLQ-LC13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Capacity</measure>
    <time_frame>For 24 months upon enrollment</time_frame>
    <description>Pulmonary function test parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in the 1st second</measure>
    <time_frame>For 24 months upon enrollment</time_frame>
    <description>Pulmonary function test parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular function: Longitudinal strain</measure>
    <time_frame>For 12 months upon enrollment</time_frame>
    <description>Echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular function: Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>For 12 months upon enrollment</time_frame>
    <description>Echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular function: Ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e')</measure>
    <time_frame>For 12 months upon enrollment</time_frame>
    <description>Echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular function: N-terminal prohormone of brain natriuretic peptide (NT-proBNP)</measure>
    <time_frame>For 12 months upon enrollment</time_frame>
    <description>Blood Sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular function: High-sensitive Troponin-T (hsTNT)</measure>
    <time_frame>For 12 months upon enrollment</time_frame>
    <description>Blood Sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry parameters of MRgRT as compared to CT-based SBRT techniques</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Diffusion Coefficient (ADC)</measure>
    <time_frame>3 months upon SBRT.</time_frame>
    <description>Translational imaging biomarkers based on multiparametric MRI (T1w, T2w and diffusion-weighted) for early detection of pulmonary toxicity and tumor relapse (explorative).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokines</measure>
    <time_frame>Immediately and 3 months upon SBRT.</time_frame>
    <description>Translational blood biomarkers (explorative).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotypes of peripheral blood mononucleated cells (PBMC)</measure>
    <time_frame>Immediately and 3 months upon SBRT.</time_frame>
    <description>Translational blood biomarkers for early detection of pulmonary toxicity and tumor relapse (explorative).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Level 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose 50 Gy, (10 x 5 Gy single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose 55 Gy, (10 x 5.5 Gy single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose 60 Gy, (10 x 6 Gy single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose 65 Gy, (10 x 6.5 Gy single dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic body radiotherapy (SBRT)</intervention_name>
    <description>level 0 (de-escalation): 10 x 5.0Gy&#xD;
level 1 (start): 10 x 5.5Gy&#xD;
level 2: 10 x 6.0Gy&#xD;
level 3: 10 x 6.5Gy</description>
    <arm_group_label>Level 0</arm_group_label>
    <arm_group_label>Level 1</arm_group_label>
    <arm_group_label>Level 2</arm_group_label>
    <arm_group_label>Level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ultracentral location of the lung tumor, which is defined as an expected contact or&#xD;
             overlap of the planning target volume with the proximal bronchial tree or esophagus at&#xD;
             the time of consultation&#xD;
&#xD;
          -  indication for SBRT of the ultracentral pulmonary tumor&#xD;
&#xD;
          -  maximum diameter of the ultracentral pulmonary tumor &lt; 5cm&#xD;
&#xD;
          -  age &gt; 18 years of age&#xD;
&#xD;
          -  Karnofsky Performance Score &gt; 70% (ECOG Score 0 - 2)&#xD;
&#xD;
          -  ability to lie still on the MR-linac table for at least one hour&#xD;
&#xD;
          -  ability to hold one's breath for more than 20 seconds&#xD;
&#xD;
          -  successful completion of MRgRT simulation&#xD;
&#xD;
          -  for women with childbearing potential, adequate contraception.&#xD;
&#xD;
          -  ability of subject to understand character and individual consequences of the clinical&#xD;
             trial&#xD;
&#xD;
          -  written informed consent (must be available before enrolment in the trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal of the patients to take part in the study&#xD;
&#xD;
          -  previous radiotherapy of the lung and mediastinum, if previous and current target&#xD;
             volumes overlap&#xD;
&#xD;
          -  patients who have not yet recovered from acute toxicities of prior therapies&#xD;
&#xD;
          -  (planned) treatment with vascular endothelial growth factor (VEGF) inhibitors, e.g.&#xD;
             Bevacizumab, within the time interval 2 weeks before and 2 weeks after SBRT&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  contraindications against performing MRI scans (pacemakers, other implants making MRI&#xD;
             impossible)&#xD;
&#xD;
          -  participation in another competing clinical study or observation period of competing&#xD;
             trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliane HÃ¶rner-Rieber, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliane HÃ¶rner-Rieber, PD</last_name>
    <phone>+49 6221-56</phone>
    <phone_ext>8201</phone_ext>
    <email>Juliane.Hoerner-Rieber@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adriane Hommertgen, PhD</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>8201</phone_ext>
    <email>adriane.hommertgen@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Heidelberg, Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Department Head</investigator_title>
  </responsible_party>
  <keyword>SBRT</keyword>
  <keyword>IGRT</keyword>
  <keyword>MR-guidance</keyword>
  <keyword>ultracentral lung tumor</keyword>
  <keyword>NSCLC</keyword>
  <keyword>oligometastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

